Want to see AU:MSX full AI Analyst Report?
Neuroscientific Biopharmaceuticals Ltd. (MSX) AI Stock Analysis
Neuroscientific Biopharmaceuticals Ltd.
(ASX:MSX)
The overall score is at the minimum of 37, reflecting a highly speculative and distressed profile. The company's financial foundation is crumbling, with zero revenue and a widening cash burn that is rapidly consuming its only strength—a debt-free balance sheet. This fundamental weakness is confirmed by a completely broken technical trend and an uninvestable valuation. The stock is a high-risk proposition with no discernible positive catalysts in the provided data.
Neuroscientific Biopharmaceuticals Ltd. (MSX) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 21.04M
- Dividend Yield
- ―
- Average Volume (3M)
- 165.23K
- Price to Earnings (P/E)
- -3.9
- Beta (1Y)
- 0.52
- Revenue Growth
- ―
- EPS Growth
- -10.32%
- Country
- Australia
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical re...
Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview
Summary
Financial performance is critically weak. The company has zero revenue, persistent and substantial net losses, and deeply negative cash flows with a widening cash burn. The only mitigating factor is a strong, debt-free balance sheet, but this is rapidly eroding due to operating losses.
Income Statement
8Very NegativeBalance Sheet
65PositiveCash Flow
10Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 2.21M | 4.95M | 0 |
| Gross Profit | -1.38M | -1.38M | -92.78K | -91.34K | -57.85K | -64.92K |
| EBITDA | -3.72M | -3.72M | -1.92M | -1.80M | -5.96M | -10.37M |
| Net Income | -4.69M | -4.69M | -1.85M | 324.21K | -1.07M | -10.44M |
Balance Sheet | ||||||
| Total Assets | 15.18M | 15.18M | 16.96M | 5.44M | 5.29M | 7.74M |
| Cash, Cash Equivalents and Short-Term Investments | 4.63M | 4.63M | 7.27M | 4.95M | 4.91M | 7.22M |
| Total Debt | 87.04K | 87.04K | 0 | 0 | 0 | 0 |
| Total Liabilities | 374.89K | 374.89K | 149.22K | 85.68K | 597.36K | 2.22M |
| Stockholders Equity | 14.81M | 14.81M | 16.81M | 5.35M | 4.69M | 5.52M |
Cash Flow | ||||||
| Free Cash Flow | -2.78M | 0 | -941.33K | 42.43K | -2.30M | -6.95M |
| Operating Cash Flow | -2.78M | -2.61M | -941.33K | 44.25K | -2.30M | -6.94M |
| Investing Cash Flow | -1.83M | -2.00M | -36.04K | -1,815 | 0 | -3,866 |
| Financing Cash Flow | -30.26K | -30.26K | 3.29M | 0 | 0 | 0 |
Neuroscientific Biopharmaceuticals Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MSX, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 7.24 is Positive, neither overbought nor oversold. The STOCH value of 46.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MSX.
Neuroscientific Biopharmaceuticals Ltd. Peers Comparison
Overall Rating
AU:NEU74Outperform
AU:ZLD52Neutral
AU:ACW44Neutral
AU:ATH44Neutral
AU:PYC44Neutral- AU:MSX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:NEU | 74Outperform | AUD 2.58B | 128.62 | 6.03% | 0.74% | -68.00% | -86.31% |
| AU:ZLD | 52Neutral | AUD 5.95M | -1.56 | 80.84% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:ACW | 44Neutral | AUD 162.72M | -8.75 | -103.42% | ― | ― | 5.88% |
| AU:ATH | 44Neutral | AUD 60.72M | -2.40 | -48.25% | ― | ― | -16.21% |
| AU:PYC | 44Neutral | AUD 1.85B | -31.81 | -10.31% | ― | ― | 39.63% |
| AU:MSX | 37Underperform | AUD 19.49M | -3.88 | -30.02% | ― | ― | -10.32% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:MSX | Neuroscientific Biopharmaceuticals Ltd. | 0.05 | -0.09 | -64.29% | |
| AU:ACW | Actinogen Medical Limited | 0.04 | 0.01 | 16.67% | |
| AU:NEU | Neuren Pharmaceuticals Limited | 20.36 | -0.44 | -2.10% | |
| AU:ATH | Alterity Therapeutics Ltd. | 0.27 | -0.23 | -47.00% | |
| AU:ZLD | Zelira Therapeutics Ltd. | 0.50 | 0.15 | 42.86% | |
| AU:PYC | PYC Therapeutics Limited | 1.88 | 0.69 | 57.85% |
Neuroscientific Biopharmaceuticals Ltd. Corporate Events
NeuroScientific Secures FDA Support as StemSmartâ„¢ Moves Toward Phase 2
NeuroScientific Biopharmaceuticals reported that a recent pre‑IND meeting with the U.S. FDA delivered positive feedback on the planned Phase 2 trial of StemSmart™ in refractory Crohn’s disease, confirming the trial design and suppor...
NeuroScientific Biopharmaceuticals appoints new CFO as Crohn’s program advances
NeuroScientific Biopharmaceuticals Ltd., an Australian biotech specialising in immune-mediated inflammatory disorders, is advancing its StemSmart stem cell technology for severe, treatment-resistant Crohn’s disease. The company aims to deliver...
NeuroScientific Wins FDA Backing for StemSmart Crohn’s Trial
NeuroScientific Biopharmaceuticals has secured positive regulatory feedback from the U.S. Food and Drug Administration on its planned Phase 2 trial of StemSmart in patients with refractory Crohn’s disease in the United States and Australia. The...
NeuroScientific Taps Southern Star to Run Phase 2 Crohn’s Trial
NeuroScientific Biopharmaceuticals has appointed Australian contract research organisation Southern Star Research to run its planned Phase 2 clinical trial of the StemSmart mesenchymal stem cell platform in patients with refractory Crohn’s dise...
NeuroScientific Biopharmaceuticals Sets October 2026 AGM to Review Governance and Board
NeuroScientific Biopharmaceuticals Ltd has called its Annual General Meeting for 10.00am AWST on 15 October 2026 in Perth, Western Australia. Shareholders eligible to vote will be those on the register as of 5.00pm AWST on 13 October 2026, and they a...
NeuroScientific Sets October AGM, Pushes Digital Access and Proxy Voting
NeuroScientific Biopharmaceuticals Ltd has scheduled its Annual General Meeting for 15 October 2026 at 10:00am AWST in Perth and is encouraging shareholders to participate via directed proxy voting and advance registration. The company will primarily...
NeuroScientific Biopharmaceuticals Changes External Auditor Ahead of October AGM
NeuroScientific Biopharmaceuticals Ltd has announced a change in its external audit arrangements, with Horizon Nexus (WA) Audit Pty Ltd resigning as auditor after receiving consent from the corporate regulator. In.Corp Audit & Assurance Pty Ltd h...
Neuroscientific Biopharmaceuticals Lodges Updated ASX Governance Disclosures
Neuroscientific Biopharmaceuticals Ltd., an ASX-listed biopharmaceutical company developing neuroscience-focused therapies, provides governance information to investors through its website, including its board charter and corporate governance stateme...
NeuroScientific Biopharmaceuticals Widens Annual Loss Despite Surge in Income
NeuroScientific Biopharmaceuticals Limited reported income from ordinary activities of $629,398 for the year ended 30 June 2026, a 278.98% increase on the prior year, but the loss from ordinary activities after tax widened to $4.69 million, reflectin...
NeuroScientific Advances StemSmart Crohn’s Program After Promising Patient Results
NeuroScientific Biopharmaceuticals reported that five patients with fistulising Crohn’s disease treated with its StemSmart therapy under Australia’s Special Access Scheme all improved, with four achieving a clinical response and no seriou...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026